Press Releases Ensysce Biosciences, Inc.

Equities

ENSC

US2936024056

Market Closed - Nasdaq Other stock markets 02:00:01 11/05/2024 am IST			5-day change	1st Jan Change
0.524 ^USD	-3.23%		-6.60%	-50.57%

21/03	Transcript : Ensysce Biosciences, Inc., Q4 2023 Earnings Call, Mar 21, 2024
15/03	Ensysce Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ensysce Biosciences Presentation from the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published	22/04	AQ
Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference	10/04	AQ
Ensysce Biosciences : Corporate Overview	28/03	PU
Ensysce Biosciences Receives Positive Nasdaq Listing Determination	28/02	AQ
Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds	14/02	AQ
Ensysce Biosciences Selected to Present at American Association of Pain Medicine Annual Conference	07/02	AQ
Ensysce Biosciences to Present Groundbreaking Oral Overdose Protection for Opioids at the 5th Annual NIH HEAL Meeting	26/01	AQ
Ensysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPAR	24/01	AQ
Ensysce Biosciences Issues 2024 Shareholder Letter	09/01	AQ
Ensysce Biosciences Postpones Special Meeting of Stockholders to December 29, 2023	20/12	AQ
Ensysce Biosciences Announces Key Efficacy Data for Lead Analgesic	15/12	AQ
Ensysce Biosciences Discusses TAAP and MPAR Applications and OncoZenge Partnership with the Stock Day Podcast	12/12	AQ
Ensysce Biosciences Announces Completion of $1.7 Million Convertible Note Financing	30/11	AQ
Ensysce Biosciences and OncoZenge Announce Letter of Intent for the Co-development of BupiZenge™ in the United States	28/11	AQ
Ensysce Biosciences Announces Enrollment Completion for PF614-201 Clinical Study	17/11	AQ
Ensysce Biosciences Secures $1.7 Million Convertible Note Financing	25/23/25	AQ
Ensysce Biosciences : Secures $1.7 Million Convertible Note Financing - Form 8-K	24/23/24	PU
Ensysce Biosciences Announces Poster Presentation at the AAPS 2023 PharmSci 360	19/23/19	AQ
Ensysce Biosciences Releases 'Highlights Video' of PAINWeek 2023 Symposium	16/23/16	AQ
Ensysce Biosciences Chief Medical Officer to Chair the 17th Annual Pain Therapeutics Summit	12/23/12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Ensysce Biosciences, Inc.

Equities

ENSC

US2936024056

Press Releases

Filters